Aroa Biosurgery (ASX:ARX) has completed a pivotal clinical trial called the Symphony trial, aimed at treating diabetic foot ulcers, a significant complication of diabetes. The trial indicates that wounds treated with Symphony, a new skin substitute utilizing advanced extracellular matrix technology, healed more effectively than those receiving standard care within 12 weeks. This success is viewed as a crucial step in gathering clinical evidence to support Symphony’s adoption in medical practice, especially as it may aid in meeting stringent healthcare requirements in the U.S. for market access and reimbursement.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://biotechdispatch.com.au/news/aroa-biosurgery-reports-promising-trial-milestone-for-advanced-wound-treatment
